NMS-P626, with the CAS number 942471-37-6, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a small molecule inhibitor, specifically targeting certain protein interactions that are implicated in various diseases, including cancer. The compound is characterized by its unique molecular structure, which allows it to interact selectively with specific biological targets, thereby modulating their activity. NMS-P626 has been studied for its efficacy in preclinical models, demonstrating promising results in inhibiting tumor growth and promoting apoptosis in cancer cells. Additionally, its pharmacokinetic properties, such as solubility and bioavailability, are critical for its development as a therapeutic agent. Ongoing research aims to further elucidate its mechanism of action, optimize its chemical properties, and evaluate its safety and effectiveness in clinical settings. Overall, NMS-P626 represents a significant advancement in the search for targeted cancer therapies.

NMS-P626

942471-37-6: NMS-P626, with the CAS number 942471-37-6, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a small molecule inhibitor, specifically targeting certain protein interactions that are implicated in various diseases, including cancer. The compound is characterized by its unique molecular structure, which allows it to interact selectively with specific biological targets, thereby modulating their activity. NMS-P626 has been studied for its efficacy in preclinical models, demonstrating promising results in inhibiting tumor growth and promoting apoptosis in cancer cells. Additionally, its pharmacokinetic properties, such as solubility and bioavailability, are critical for its development as a therapeutic agent. Ongoing research aims to further elucidate its mechanism of action, optimize its chemical properties, and evaluate its safety and effectiveness in clinical settings. Overall, NMS-P626 represents a significant advancement in the search for targeted cancer therapies.

<p>NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.</p>

CAS 942471-37-6

NMS-P626

NMS-P626

Ref: TM-T200149